Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02960555 · ClinicalTrials.gov registry record · Phase 2
Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
A Phase 2 study of Smoldering Plasma Cell Myeloma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 3
- Study locations
NCT02960555 is a Phase 2 study of Smoldering Plasma Cell Myeloma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 61 participants, below the 133-participant average among 9 other Smoldering Plasma Cell Myeloma trials with a reported enrollment target (54% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT02960555, a Phase 2 study of Smoldering Plasma Cell Myeloma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multi-center, open label, phase II study designed to evaluate the efficacy of isatuximab with or without lenalidomide when given to patients with high risk smoldering multiple myeloma.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Isatuximab
Study Locations (3)
New York
- Mount Sinai Hospital - New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2017-02-08 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02960555
The ClinicalTrials.gov registry entry for NCT02960555 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 133-participant average among 9 other Smoldering Plasma Cell Myeloma trials with a reported enrollment target (54% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoldering Plasma Cell Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02960555 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New York, Texas.
Frequently Asked Questions
What is clinical trial NCT02960555 about?
NCT02960555 is a clinical study titled "Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)". This is a multi-center, open label, phase II study designed to evaluate the efficacy of isatuximab with or without lenalidomide when given to patients with high risk smoldering multiple myeloma.
What is the current status of trial NCT02960555?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2017-02-08. Estimated completion is 2030-04-30.
What conditions does trial NCT02960555 study?
This clinical trial studies the following conditions: Smoldering Plasma Cell Myeloma.
What interventions are being tested in trial NCT02960555?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Isatuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02960555?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02960555 being conducted?
This trial has 3 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Plasma Cell Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 2
-
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
ACTIVE NOT RECRUITING · Phase 2
-
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
RECRUITING
-
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
RECRUITING · Phase 3
-
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
RECRUITING · NA
-
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.